Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
We recount a single-center experience with cardiac immunity-related adverse effects in patients treated with immune checkpoint inhibitors. Of 2,830 patients, 9 patients (0.3%) developed cardiac immunity-related adverse effects (4 cases of cardiomyopathies, 2 of myocarditis, 2 of acute pericarditis,...
Main Authors: | Johnny Chahine, MD, Patrick Collier, MD, PhD, Anjli Maroo, MD, W.H. Wilson Tang, MD, Allan L. Klein, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | JACC: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666084919306916 |
Similar Items
-
Pericardial effusion under nivolumab: case-reports and review of the literature
by: Saade Anastasia, et al.
Published: (2019-10-01) -
Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01) -
Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01) -
Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event
by: Jolanta Pach, BA, et al.
Published: (2021-07-01) -
Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Ming Yuan, et al.
Published: (2021-10-01)